Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Capsules × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡